PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31253599-4	2019	The purpose of this study was to compare the efficacy and safety of mycophenolate mofetil versus cyclophosphamide for the induction treatment of nonlife-threatening relapses of proteinase 3-ANCA- and myeloperoxidase-ANCA-associated vasculitis.	Mycophenolic Acid	68-89	myeloperoxidase	Homo sapiens	177-215	
30918194-5	2019	Corticosteroids and mycophenolate mofetil were administered as for ANCA vasculitis, and the serum creatinine, abnormal urinalysis and MPO-ANCA titer all gradually ameliorated.	Mycophenolic Acid	20-41	myeloperoxidase	Homo sapiens	134-137	
35064793-13	2022	The combined effects of myeloperoxidase concentration and renal function resulted in a sixfold range of MPA dose.	Mycophenolic Acid	104-107	myeloperoxidase	Homo sapiens	24-39	
18538114-0	2008	Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity.	Mycophenolic Acid	0-21	myeloperoxidase	Homo sapiens	30-33	
23517575-10	2013	cyclophosphamide pulses monthly for 6 doses, followed by mycophenolate mofetil that resulted in normal lung function tests, hemoglobin concentration, and anti-MPO level within four subsequent weeks.	Mycophenolic Acid	57-78	myeloperoxidase	Homo sapiens	159-162